Abstract. The present study characterizes the effects of resveratrol (Res) on vascular endothelial growth factor (VEGF) secretion in retinal pigment epithelial (RPE) cells. ARPE-19 cells were treated with CoCl 2 , a hypoxia mimetic agent. CoCl 2 treatment increased protein levels of hypoxia inducible factor-1α (HIF-1α) and CXC-chemokine receptor 4 (CXCR4), and secretion of VEGF. To confirm the effects of Res on VEGF secretion, the human umbilical vein endothelial cell tube formation assay was performed with conditioned medium from Res-treated ARPE-19 cells. The well-known antioxidant Res effectively blocked these effects and reduced phosphorylation of nuclear factor (NF)-κB, an upstream activator of CXCR4. 
Introduction
Neovascularization is a major cause of common eye diseases, such as age-related macular degeneration (AMD), diabetic retinopathy, and retinopathy of prematurity (ROP) that result in blindness (1) . New vessels that are generated by neovascularization usually undergo repeated regeneration, which can easily lead to bleeding and vessel destruction due to stress caused by increased permeability. A number of the pathways that result in neovascularization have been identified (2) . The majority of these pathways, such as the protein kinase B (AKT) pathway, the nuclear factor of activated T-cells (NFAT) signaling pathway, and the Nox2-generated reactive oxygen species (ROS) pathway, are associated with increased vascular endothelial growth factor (VEGF) expression (3) (4) (5) . Therefore, VEGF is a major component of the neovascularization process.
VEGF-A, also termed VEGF, is a member of the cysteine-knot superfamily of growth factors. The characteristics of VEGF are determined by a cysteine residue (6, 7) . Increased secretion of VEGF induces neovascularization, and anti-VEGF therapy with bevacizumab is effective in the suppression of neovascularization (8) . Certain conditions, such as diabetes, trauma and infection (9) , can induce hypoxia, which results in the increased expression of VEGF in the eye (10) . Secretion of VEGF is also generally observed in cancer cells. In certain types of cancer, the cell secretes VEGF locally to stimulate the surrounding endothelial cells for neovascularization (11) . Retinal pigment epithelial (RPE) cells are a source of VEGF in the eye (12) . RPE cells form a monolayer structure at the back of the eye, and supply nutrients and remove waste from the surrounding tissues. Although there are several pathways that regulate VEGF expression, the present study focuses on the interaction between CXC-chemokine receptor 4 (CXCR4) and VEGF.
CXCR4 is a well-known hypoxia-related protein (13) . Studies of cancer cells revealed that CXCR4 expression is increased during hypoxia and mediates VEGF upregulation (14, 15) . This suggested that CXCR4 could be a useful target for inhibition of neovascularization.
Resveratrol Neurosurgery, Institute of Health Sciences, School of Medicine, Gyeongsang National University, Jinju, Gyeongnam 660-751, Republic of Korea on inflammation, apoptosis and neovascularization (16, 17) . Furthermore, Res is particularly effective as an antioxidant in hypoxic conditions (18) . Res also prevents or mitigates the effects of eye diseases, such as retinal detachment and diabetic retinopathy (19) (20) (21) (22) . The main target of Res is nuclear factor (NF)-κB, which is a major factor of the SDF-1/CXCR4 axis (23) .
In this study, the major regulators of hypoxia-induced VEGF secretion in the ARPE-19 human retinal epithelial cell line were characterized. The present study focused on the NF-κB, CXCR4 and VEGF pathways, and the effect of Res on neovascularization induced by hypoxia.
Materials and methods
Reagents. High-glucose Dulbecco's modified Eagle's medium F12 (DMEM-F12), penicillin, streptomycin and fetal bovine serum (FBS) were purchased from Gibco (Grand Island, NY, USA). TRIzol reagent was purchased from Invitrogen Life Technologies (Carlsbad, CA, USA). Res was purchased from Tocris (Ellisville, MO, USA), SDF-1 was purchased from R&D systems (Minneapolis, MN, USA) and dimethylsulfoxide (DMSO) was purchased from Amresco (Solon, OH, USA). Antibodies specific for hypoxia inducible factor-1α (HIF-1α; cat. no. 3716S) and phospho-NF-κB (cat. no. 3033S) were purchased from Cell Signaling Technology Inc. (Danvers, MA, USA), anti-CXCR4 antibodies (cat. no. ab2074) were purchased from Abcam (Cambridge, UK), and anti-α-tubulin antibodies (cat. no. T5168) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Ammonium pyrrolidinethiocarbamate (PDTC), NF-κB inhibitor and AMD3100 (a CXCR4 antagonist), were purchased from Sigma-Aldrich. BD Matrigel™ Basement Membrane Matrix was purchased from BD Biociences (Bedford, MA, USA). Resveratrol was dissolved in DMSO, PDTC and AMD3100 were dissolved in water, and SDF-1 was dissolved in phosphate-buffered saline (PBS).
Cell culture and treatment. ARPE-19 cells (American Type Culture Collection, Manassas, VA, USA) were cultured in DMEM F12 supplemented with 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin at 37˚C in an atmosphere with 5% CO 2 at 70% confluence. For some experiments, ARPE-19 cells were cultured in DMEM-F12 with 0.1% FBS in the presence of designated concentrations of VEGF protein and/or Res (10-50 µM). Cells were exposed to CoCl 2 for 6 h prior to western blotting. Cells were grown as monolayer.
Western blotting. ARPE-19 cells were plated on 100-mm dishes at 1x10 6 cells/dish. Following treatment, cells were harvested, centrifuged at 890 x g for 1 min, and lysed in lysis buffer [50 mM Tris-Cl (pH 8.0), 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS) and 0.02% sodium azide, which were purchased from Amresco; 1% NP-40 and 0.5% sodium deoxycholate, which were purchased from Sigma-Aldrich, and proteinase inhibitor cocktail (containing phenylmethylsulphonyl fluoride, 100 µg/ml; aprotinin, 1 µg/ml; leupeptin, 0.5 µg/ml; Roche, Nutley, NJ, USA)]. Total protein concentration was determined using a bicinchoninic acid protein assay system (Thermo Fisher Scientific, Waltham, MA, USA). An equal volume of 4X SDS sample buffer was added to 30 µg of protein extract and the samples were boiled for 5 min. Equivalent quantities of total protein (15-20 µg) were separated by SDS-PAGE on 8-10% polyacrylamide gels and then transferred to nitrocellulose membranes (GE Healthcare, Little Chalfont, UK) at 15 V for 30 min using a semi-dry transfer apparatus (Bio-Rad Laboratories, Hercules, CA, USA) submerged in transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol; pH 8.3). The membrane was blocked with 5% skimmed milk in 0.1% Tween-20/Tris-buffered saline (TBST) and then incubated with anti-CXCR4 (1:1,000), anti-HIF-1α (1:1,000), anti-phospho-NF-κB (1:1,000) or anti-α-tubulin (1:10,000) antibody at 4˚C overnight. Subsequently, the blot was washed in TBST and incubated with goat anti-rabbit (cat. no. 31430) and goat anti-mouse (cat. no. 31460) immunoglobulin G secondary antibodies (Thermo Fisher Scientific; 1:10,000 dilution) for 45 min at room temperature. After washing, immunoreactivity was detected by chemiluminescence (ECL; Advansta, Menlo Park, CA, USA) using the LAS 3000 instrument (Fujifilm, Tokyo, Japan). The band intensities were assessed by Multi Gauge 3.0 software (Fujifilm).
Enzyme-linked immunosorbent assay (ELISA). ARPE-19 cells
were plated on 6-well cell culture plates at 5x10 4 cells/well. Cell culture media were supplemented with 1% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin. VEGF secretion levels were measured using a commercial human VEGF-ELISA kit from Invitrogen Life Technologies (Camarillo, CA, USA), according to the manufacturer's instructions.
Human umbilical vein endothelial cell (HUVEC) tube formation assay. ARPE-19 cells were cultured in DMEM-F12 media with 0.1% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37˚C and 5% CO 2 in the presence of the designated concentrations of Res (50 µM). ARPE-19 cells were classified into three groups: Control [Normoxia conditioned medium (CM)], 1% O 2 hypoxia-treatment (Hypoxia CM) and hypoxia + Res (50 µM) co-treatment (Hypoxia + Res CM). Cells were exposed to 1% O 2 for 24 h in a hypoxia chamber (MCO-5M; Sanyo, Osaka, Japan). The CM obtained from ARPE-19 cells was transferred to HUVECs (PromoCell, Heidelberg, Germany) that were seeded on 24-well plates coated with Matrigel™ at 1x10 5 cells/well. CM-treated HUVECs were incubated for 48 h. Tube formation was analyzed by light microscopy (U-LH100HG; Olympus Corporation, Tokyo, Japan) and ImageJ 1.46r software (National Institutes of Health, Bethesda, MD, USA).
Statistical analysis. Data are expressed as the mean ± standard error of the mean. One-way analysis of variance was performed using Dunnett's post-test. (Prism 5; GraphPad Software, La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.
Results

HIF-1α and CXCR4 protein expression, and VEGF secretion profiles ARPE-19 cells treated with a hypoxia mimetic agent.
To confirm hypoxia-induced changes in protein expression in ARPE-19 cells, cells were treated with CoCl 2 (100 µM) a hypoxia mimetic agent for 24 h. HIF-1α and CXCR4 protein levels were determined by western blotting. Expression of the hypoxia marker HIF-1α was increased by ~3.5-fold at 3 h and peaked by ~5-fold at 12 h. CXCR4 protein levels also increased at 6 h (Fig. 1A) . VEGF secretion, determined by ELISA, was significantly increased at 12 h and further increased by >5-fold at 24 h (Fig. 1B) . These results showed that CXCR4 protein was expressed in ARPE-19 cells, and that expression of HIF-1α, CXCR4 and VEGF proteins increased after hypoxia mimetic treatment, which were similar to the results found under 1% O 2 hypoxic conditions.
Res suppressed HIF-1α protein expression, NF-κB phosphorylation, CXCR4 protein expression, and VEGF secretion in ARPE-19 cells treated with a hypoxia mimetic agent. To evaluate the effects of the antioxidant Res on the increased expression of CXCR4 protein induced by CoCl 2 , cells were pre-treated with Res at three different concentrations (10-50 µM). After 2 h, CoCl 2 (100 µM) was added for a further 6 h. The expression of phosphorylated NF-κB protein, a major target of Res, was also examined. Res treatment reversed the CoCl 2 -induced increases in the levels of HIF-1α, p-NF-κB and CXCR4 protein expression in a dose-dependent manner. The levels of HIF-1α, p-NF-κB and CXCR4 protein expression were reduced by ~80, 60 and 50% by 50 µM resveratrol, respectively ( Fig. 2A) , and similar effects on VEGF secretion were observed (Fig. 2B) . These results showed that 50 µM Res effectively inhibited the phosphorylation of NF-κB, expression of HIF-1α and CXCR4, and secretion of VEGF.
PDTC and AMD3100 suppress VEGF secretion in hypoxia mimetic-treated ARPE-19 cells.
To investigate the effects of NF-κB and CXCR4 on VEGF secretion, cells were treated with PDTC (10 and 20 µM) and AMD3100 (100 and 300 µM) for 12 h in combination with CoCl 2 . PDTC and AMD3100 treatments dose-dependently reduced the CoCl 2 -induced VEGF secretion respectively (Fig. 3) . These results showed that Res is able to suppress VEGF secretion through inhibition of NF-κB and CXCR4.
Res suppresses SDF-1-induced VEGF secretion. As inhibition of CXCR4 suppressed VEGF secretion, it was then analyzed whether Res can suppress VEGF secretion induced by ligand-receptor interaction of CXCR4. Cells were treated with SDF-1 (30 ng/ml), a ligand of CXCR4, alone or in combination with Res (50 µM) for 12 h. SDF-1 induced-secretion of VEGF in ARPE-19 cells was suppressed by co-treatment with Res (50 µM) (Fig. 4) . with Normoxia CM and Res (50 µM) served as a negative control (Fig. 5) .
Suppression of HUVEC tube formation by CM from
Discussion
In this study, it was determined using CoCl 2 -induced hypoxia mimetic conditions that there is an association between CXCR4 and VEGF in ARPE-19 cells, and it was assessed whether Res could effectively suppress neovascularization by targeting interactions between CXCR4 and VEGF. Similar to other studies, it was confirmed that CXCR4 and VEGF levels were increased during chemically-induced hypoxia (24, 25) . Furthermore, it was demonstrated that Res inhibited CXCR4 expression and VEGF secretion, and suppressed HUVEC tube formation.
HIF-1α is widely used as a hypoxia marker. During hypoxia, HIF-1α rapidly accumulates as the activation of enzymes responsible for HIF-1α degradation is reduced (26) . CoCl 2 is a well-known chemical inhibitor of HIF-1α degradation (27) . Therefore, CoCl 2 -induced HIF-1α accumulation may result in increased expression of CXCR4 and secretion of VEGF, which is similar to the results obtained following hypoxia.
The CoCl 2 -induced increase in CXCR4 expression and VEGF secretion was suppressed by Res in a dose-dependent manner. The changes in VEGF secretion paralleled the pattern of CXCR4 expression; therefore, it was hypothesized that CXCR4 is important in the regulation of VEGF secretion. Recent studies verified the interaction between CXCR4 and VEGF in several cell types (28, 29) . In the present study, Res also suppressed phosphorylation of NF-κB. Certain studies have found that NF-κB activation is associated with CXCR4 expression (30, 31) . Furthermore, NF-κB was found to be an important component of the SDF-1/CXCR4 axis (32) . NF-κB is a typical transcription factor that is activated through phosphorylation (23) . A recent study showed that phosphorylation of NF-κB increases during hypoxia (33) . Therefore, suppression of NF-κB phosphorylation by Res could cause suppression of CXCR4 expression. It was hypothesized that Res inhibits phosphorylation of NF-κB leading to suppression of CXCR4 protein expression, which then affects VEGF secretion. The results of PDTC and AMD3100 treatment supported that. NF-κB was recently shown to be involved in the regulation of CXCR4 transcription, suggesting that NF-κB regulates CXCR4 at the mRNA level (34) .
SDF-1 and CXCR4 are part of a ligand-receptor axis. As SDF-1 is a ligand of CXCR4, an increase in SDF-1 induces CXCR4 activity (35) . In the present study, it was found that Res significantly affected the induction of VEGF secretion and mRNA expression (data not shown) by SDF-1. Thus demonstrating that Res affects the ligand-receptor interaction of SDF-1 and CXCR4, through suppression of CXCR4 expression. The present study suggests that Res may be a useful therapeutic agent that suppresses VEGF secretion in RPE cells through CXCR4 inhibition, thus reducing neovascularization.
The present study also provided data supporting the in vitro experiments using the HUVEC tube formation assay to investigate the effects of Res on retinal neovascularization induced by VEGF secreted from RPE cells. VEGF secretion by ARPE-19 cells was triggered by hypoxia and conditioned medium obtained from the treated cells was applied to HUVECs. HUVEC tube formation was significantly increased by the addition of conditioned media from ARPE-19 cells with chemically induced hypoxia suggesting that VEGF secretion from RPE cells substantially affected neovascularization. Moreover, this effect could be inhibited by co-treatment of the ARPE-19 cells with Res. Additional studies have shown that Res effectively inhibits neovascularization in several cancer cell types (36, 37) .
In conclusion, an increase in CXCR4 expression during CoCl 2 chemically induced hypoxia in ARPE-19 cells was confirmed, accompanied by an increase in VEGF secretion. Res suppression of these responses may be through the inhibition of CXCR4 and NF-κB, suggesting that Res could be used as a therapeutic agent to suppress retinal neovascularization by targeting CXCR4.
